Abivax S.A.
- Last sale
- Nov 12, 2026 · -1.19%
- Market cap
- $7.09B
- 78.54M shares
- Filings
- 106
—
—
—FY 2025N/M FY25 yoy
FY 2025N/M FY25 yoy
FY 2025derivedN/M FY25 yoy
FY 2025N/M FY25 yoy
FY 2025+258.3% FY25 yoy
- $7.09B
- —
- —
- —
- —
- —
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Research And Development
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | €177,761,000 | reported | |
| FY 2024 | 2024-12-31 | €146,532,000 | reported | |
| FY 2023 | 2023-12-31 | €103,176,000 | reported | |
| FY 2022 | 2022-12-31 | €48,295,000 | reported | |
| FY 2021 | 2021-12-31 | €47,781,000 | reported |
Pharmaceutical preparations
Abivax S.A. is the 43rd largest of the 552 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
ALKSAlkermes plc.$1.5B5.2%16.4%$7.9BCYTKCytokinetics Inc$88.0M376.6%891.6%$7.8BRYTMRhythm Pharmaceuticals, Inc.$189.8M45.8%103.6%$7.6BAXSMAxsome Therapeutics, Inc.$638.5M65.5%28.7%$7.6BAMRXAmneal Pharmaceuticals, Inc.$3.0B8.0%2.4%$7.5BORKAOruka Therapeutics, Inc.———$7.1B
ABVXAbivax S.A. (this company)———$7.1B
BLTEBelite Bio, Inc———$6.7BARWRArrowhead Pharmaceuticals, Inc.$450.8M45.6%160.6%$6.7BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Abivax S.A. · CIK 1956827 · Engraved from SEC EDGAR